Program
aprocitentan
Also written as “Aprocitentan”, “Aprocitentan 25 mg” and “Aprocitentan tablets(SYH9108)”.
Its studies are mostly in Hypertension · Liver Diseases · Essential Hypertension · Renal Insufficiency, led by 2 companies.
Drug pageAprocitentan: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Idorsia Pharmaceuticalsits history only | 130 open or running | phase 3since May 17, 2018 | Nov 9, 2015 | none ahead |
| CSPC Pharmaceutical Group | 11 open or running | phase 3since May 29, 2026 | May 29, 2026 | Dec 28, 2029phase 3 · NCT07635914 |
Also a collaborator on its studies: Johnson & Johnson.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CSPC Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2016Named aprocitentanINNProposed as its International Nonproprietary Name in WHO's List 116
- May 29, 2026First study: phase 3 study in Resistant HypertensionFirst studyNCT07635914 · 382 planned
Ahead
- Dec 28, 2029Primary completion: phase 3 study in Resistant HypertensionNCT07635914
TargetBeta
“Endothelin receptor, ET-A/ET-B antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bosentanrule | Johnson & Johnson | phase 4 | 37 |
Studies
The one study CSPC Pharmaceutical Group leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07635914Resistant Hypertension | 3 | Not yet recruiting | Dec 28, 2029 | 382 |
How it is read
Names in the registry
- “Aprocitentan”, 5 entries
- “Aprocitentan 25 mg”, 4 entries
- “Aprocitentan tablets(SYH9108)”, 1 entry
- “Aprocitentan 12.5 mg”, 1 entry
- “14C-radiolabeled ACT-132577”, 1 entry
Conditions, from the studies’ own filings
- Hypertension, 3 studies
- Liver Diseases, 1 study
- Essential Hypertension, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.